Semaglutide vs Tirzepatide: Research Comparison
Single agonist vs dual agonist — how semaglutide and tirzepatide differ at the receptor level, for metabolic research.
Semaglutide and tirzepatide are the two most-studied incretin research compounds. The core difference is how many receptors each one targets. For in-vitro laboratory research only.
Receptor targets
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual agonist: it activates both the GIP receptor and the GLP-1 receptor. This dual mechanism is the defining distinction and the reason tirzepatide is studied as a distinct generation of incretin compound.
Research context
Both are studied in appetite-regulation, energy-expenditure, and glucose-dependent insulin-signaling models. The dual GIP/GLP-1 activity of tirzepatide makes it a frequent comparator in studies examining whether multi-receptor engagement changes metabolic outcomes versus single-receptor GLP-1 agonism.
Where retatrutide fits
If semaglutide is single-agonist and tirzepatide is dual-agonist, retatrutide is the triple-agonist (GIP + GLP-1 + glucagon) — see our GLP-1 research overview for the full cluster.
Research kits
Both ship lyophilized in multi-vial research kits from our US facility with tracking: semaglutide and tirzepatide. Reconstitute with bacteriostatic water using the calculator.
Frequently asked questions
Is tirzepatide stronger than semaglutide?
They differ mechanistically rather than simply in strength: semaglutide targets GLP-1 alone, while tirzepatide targets both GIP and GLP-1. Research compares the two to study whether dual-receptor engagement changes metabolic outcomes.
Can I study semaglutide and tirzepatide side by side?
Yes — both are available as research-use-only kits supplied lyophilized in multi-vial research kits, and they're common comparators in incretin research.